Back Login to subscribe 🔔 Set Alert

CNTB Connect Biopharma Holdings Limited Ordinary Shares

Sector: Healthcare

Industry: Biotechnology

15 min delay

Today's News Sentiment

Loading...

Upcoming Earnings

Loading...

CNTB Fundamental Data

Loading...

Similar Companies

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

CNTB Insider Transactions

Loading insider data…

CNTB News

Date	Headline	Sentiment
	Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4	86.34%
	HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target	86.21%
	HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target	86.21%
	12 Health Care Stocks Moving In Wednesday's After-Market Session	95.62%
	Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy	95.16%
	12 Health Care Stocks Moving In Wednesday's Intraday Session	94.13%
	BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5	58.62%
	Connect Biopharma shares are trading higher after the company announced preliminary topline data from its global Phase 2 study evaluating rademikibart. Results included Rademikibart reducing rate of treatment failure, rate of moderate to severe COPD exacerbations and reduced the rate of new emergency departments and hospital admissions.	94.66%
	12 Health Care Stocks Moving In Wednesday's Pre-Market Session	96.81%
	Connect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85%	85.74%

1
2
›